Concernant les diverses indemnités de départs convenues au bénéfice des dirigeants, bien que les montants maximum des indemnités soient en ligne avec le plafond de 12 mois de rémunération salariale (fixe + bonus annuel) fixé par Proxinvest, les motifs donnant droit au versement de celles-ci ne respectent pas la politique de Proxinvest qui en limite le versement à la seule hypothèse d’un départ contraint et lié à changement de contrôle.
La résolution 17 relative à l’approbation des principes de détermination des éléments de rémunération des dirigeants pour l’exercice 2017 ne peut être soutenue en raison d’un manque de transparence de la société.
Par ailleurs, le conseil est indépendant à 85,71% selon Proxinvest, ce qui est satisfaisant. Ainsi, Proxinvest soutient le renouvellement, la ratification et la nomination des administrateurs proposés aux résolutions 19, 20 et 21.
Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Based on the last sets of results and quarterly sales, it seems that the improvement in the US and the many initiatives taken by the new CEO have placed Virbac on the path to an estimated operating margin of 14.5% in 2023. Our target price of € 185 suggests more limited upside in the short term (7%): Neutral vs Buy. - Cf. report published this morning. - ...
>A collaborative agreement... - Erytech Pharma announced yesterday evening that it had entered into a strategic agreement with US company SQZ Biotech, which is specialised in cell therapies, aimed at developing a portfolio of new red-blood-cell-based immune modulation treatments. To this end, Erytech is eligible to receive up to $ 57m (up-front payment + regulatory milestone payments) and up to $ 50m in commercial milestone payments per approved treatment as well as p...
Sur la base des derniers chiffres publiés, il apparaît que l’amélioration de la situation aux USA et les nombreuses initiatives du nouveau CEO ont engagé Virbac dans une trajectoire convergeant vers une MOP de 14.5%e à horizon 2023. Notre objectif de cours de 185 € suggère un potentiel plus limité à court terme (7%) : Neutre vs Achat. - Cf. étude publiée ce jour. - ...
Item 3: Approve the Remuneration ReportThe remuneration structure is satisfactory, though accelerated vesting is possible. Potential and actual total variable remuneration exceed guidelines, but not very much. They are moderate in comparison with UK market practice. Overall, the quantum during the year was not excessive. We recommend shareholders vote in favor.
Item 3: Approve the Remuneration Report The structure is weighted more heavily towards short-term performance. One of the performance metrics for the LTI is the payment of sustainable dividends, which is not considered appropriate as executives can potentially influence the payout level. The LTI also includes relative TSR as a performance metric. Nevertheless, the quantum is not excessive and even maximum potential amounts are moderate. On balance, we recommend shareholders vote in favor. Item 4: Approve the Remuneration PolicyThe main concern with the Company's remuneration policy is that pa...
Item 2: Approve the Remuneration ReportThe remuneration structure is unsatisfactory. The main concern at the Company is that the potential maximum incentive pay including the bonus, matching shares on the deferred portion of the bonus and the LTI amounts to 1000% of base salary, which is considered grossly excessive. Actual incentive pay during the year was1.6 times the ECGS limit. Furthermore, variable remuneration is overly reliant on a single performance metric, benchmark profit before tax. A second performance criteria will be used in the coming year. We note that the Company has adjusted ...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.